Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-67953964 adjunctive treatment in major depressive disorder
2019-000695-41Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing JNJ-67953964 adjunctive treatment with Placebo adjunctive treatment (2 arms). Primary endpoint: MADRS total score at the end of double-blind treatment period in subjects not responding to placebo. Started Apr 2019; status: completed.
02
Drugs
aticaprant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2019-000695-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000695-41.